Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis

Epithelioid glioblastoma (eGBM) is a newly defined and rare GBM variant in the current WHO 2016 classification. BRAF V600E mutation is overrepresented in these tumors and there is known some morphological overlap with anaplastic epithelioid PXA (ePXA). In order to further elucidate this diagnostic c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Korshunov, Andrey (VerfasserIn) , Chavez, Lukas (VerfasserIn) , Schrimpf, Daniel (VerfasserIn) , Stichel, Damian (VerfasserIn) , Capper, David (VerfasserIn) , Sturm, Dominik (VerfasserIn) , Kool, Marcel (VerfasserIn) , Habel, Antje (VerfasserIn) , Lichter, Peter (VerfasserIn) , Pfister, Stefan (VerfasserIn) , Jones, David T. W. (VerfasserIn) , Deimling, Andreas von (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Brain pathology
Year: 2018, Jahrgang: 28, Heft: 5, Pages: 656-662
ISSN:1750-3639
DOI:10.1111/bpa.12566
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1111/bpa.12566
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bpa.12566
Volltext
Verfasserangaben:Andrey Korshunov, Lukas Chavez, Tanvi Sharma, Marina Ryzhova, Daniel Schrimpf, Damian Stichel, David Capper, Dominik Sturm, Marcel Kool, Antje Habel, Bette K. Kleinschmidt‐DeMasters, Marc Rosenblum, Oksana Absalyamova, Andrey Golanov, Peter Lichter, Stefan M. Pfister, David T.W. Jones, Arie Perry, Andreas von Deimling
Beschreibung
Zusammenfassung:Epithelioid glioblastoma (eGBM) is a newly defined and rare GBM variant in the current WHO 2016 classification. BRAF V600E mutation is overrepresented in these tumors and there is known some morphological overlap with anaplastic epithelioid PXA (ePXA). In order to further elucidate this diagnostic category, we molecularly characterized 64 pediatric and adult examples initially diagnosed as “eGBM.” Tumors were analyzed using array based methylation and direct sequencing of the BRAF and TERT genes. Our results demonstrated considerable molecular and clinical heterogeneity among eGBM cohort. Methylation patterns, copy number alterations, and mutational analysis data, in combination with clinical findings disclosed three different, well established tumor subtypes: (i) PXA-like tumors with favorable prognosis, predominantly in children and young adults (38), (ii) IDHwt GBM-like tumors with poor prognosis, mainly occurring in older adults, albeit with more frequent BRAF mutations (17), and (iii) RTK1 pediatric GBM-like neoplasms of intermediate prognosis in children and young adults, associated with chromothripsis and frequent PDGFRA amplifications (9). We conclude that the histopathologically defined eGBM do not represent a single diagnostic entity, but rather at least three molecularly and biologically distinct categories. Therefore, additional molecular testing through genome-wide molecular profiling is recommended to further stratify these rare cases.
Beschreibung:First published: 09 October 2017
Gesehen am 22.01.2020
Beschreibung:Online Resource
ISSN:1750-3639
DOI:10.1111/bpa.12566